Abstract
Introduction
Lung cancer is the third most common malignant disease and the first leading
cause of cancer death in the western world. Yet platinum agent constitutes the
current mainstay of front-line metastatic lung cancer treatment. There are
currently two platinum-based compounds that are marketed and clinically used
worldwide as treatment for non-small cell lung cancer (NSCLC): cisplatin and
carboplatin. These two drugs are combined with paclitaxel, docetaxel,
gemcitabine or vinorelbine to build the first-line treatment options. Several
different studies have been comparing or are comparing differ combinations of
these drugs. Lately gefitinib, pemetrexed and erlotinib have entered the
market and are initially used in second or third-line treatments. The
third-generation chemotherapeutic agents have expanded the therapeutic options
in the treatment of advanced NSCLC. New data on platinum-based chemotherapy
has been presented. Both Avastin and Efaproxyn have generated additional data.
In this report we are not only describing the progress of different
combinations of approved drugs but as well the progress of 22 late stage drug
candidates are described and analysed. Progress profiles and structured
information will allow you to pin-point your knowledge-base in a most
cost-effective way. New interesting phase III studies have been initiated. By
gathering information around most drugs under development for NSCLC and
specially the late stage pipeline it is has been clear that four major
therapeutic strategies generated most interesting data. With this report you
will be able to track down and foresee activities associated with the
development of new treatments for lung cancer. According to market analytical
studies, the NSCLC drug market is predicted to exceed $4 billion between 2010
and 2015. Chemotherapy drugs will experience generic erosion and three major
chemotherapy drugs go off patent before 2012; Aventis' Taxotere (docetaxel),
Bristol-Myers Squibb' s Paraplatin (carboplatin) and Eli Lilly' s Gemzar
(gemcitabine).
Example of drugs included in this study
Affinitak, Aptosyn, Bevacizumab, Carboxyamidotriazole, Cetuximab, CI-994,
Docetaxel, Efaproxyn, Erlotinib, Gefitinib, Gemcitabine, Genasense, Lapatinib
IGN-101, Mitumomab, Neovastat, Paclitaxel, Panitumumab, Pemetrexed, Targretin,
Telcyta, Tirapazamine, Trastuzumab, Vinflunine, Vinorelbine, Xcytrin, ZD-6474,
Example of companies included in this study
Abgenix, Aphton, AstraZeneca, Bristol-Myers Squibb, Cell Pathways, Eli Lilly,
Genentech, Genta, GlaxoSmithKline, ImClone, ISIS Pharmaceuticals, Ligand
Pharmaceuticals, OSI Pharmaceuticals, Pfizer, Pharmacyclics, Sanofi-Aventis,
Telik
Scope of this report
Thorough examination of status and impact of many novel drugs in development
Discussion of the challenges in current drug development, including future
clinical trials to be made, collaborations and inclusion of novel endpoints.
Case studies on major lung cancer drugs on market and in development.
Key reasons to read this report
- Explore the strengths and weaknesses associated with compounds in clinical
development.
- Scientific rationale for novel therapeutics in lung cancer, and the
results of clinical trials to date.
- Gain insight into the current challenges and commercial opportunities
associated with lung cancer
View Cart
